Biotech Breakthrough: Syngene and Orocidin Unite to Expedite Drug Development

Orocidin A/S, a part of Nordicus Partners (OTCQB: NORD), has entered into a strategic alliance with Syngene International to expedite biotech innovation. The partnership is aimed at accelerating GMP peptide development programs, specifically Orocidin's QR-0115. Syngene's innovative technology and scalable solutions will facilitate effective manufacturing with less lead time. This collaboration provides Orocidin with top-notch scientists and cutting-edge equipment, providing a strong supply chain for future commercialization. The collaboration fits Nordicus Partners' expertise in assisting Nordic and U.S. life sciences businesses expanding into the U.S. market.
Source: Globe Newswire